NASDAQ:TVRD

Tvardi Therapeutics (TVRD) Stock Price, News & Analysis

Tvardi Therapeutics logo
$1.01 -0.09 (-8.18%)
Closing price 04:00 PM Eastern
Extended Trading
$1.05 +0.04 (+3.96%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Tvardi Therapeutics Stock (NASDAQ:TVRD)

Advanced

Key Stats

Today's Range
$1.01
▼
$1.08
50-Day Range
$0.79
▼
$1.87
52-Week Range
$0.77
▼
$5.69
Volume
71,181 shs
Average Volume
372,146 shs
Market Capitalization
$13.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.40
Consensus Rating
Moderate Buy

Company Overview

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for cancer and fibrotic diseases. The company’s research focuses on STAT3, a protein involved in processes that can contribute to tumor growth and fibrosis.

Its lead drug candidate, TTI-101, is an oral small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. Tvardi is also advancing additional drug candidates based on its STAT3 research platform.

Headquartered in The Woodlands, Texas, Tvardi is focused on research and clinical development; its investigational candidates are not established commercial products. The company was founded to develop therapies targeting STAT3.

AI Generated. May Contain Errors.

Tvardi Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
76th Percentile Overall Score

TVRD MarketRank™: 
3.803872165495 of 5 stars

Tvardi Therapeutics scored higher than 76% of companies evaluated by MarketBeat, and ranked 114th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Tvardi Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 6 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Tvardi Therapeutics has a consensus price target of $9.40, representing about 830.7% upside from its current price of $1.01.

  • Amount of Analyst Coverage

    Tvardi Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Tvardi Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Tvardi Therapeutics are expected to decrease in the coming year, from ($2.23) to ($2.61) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Tvardi Therapeutics is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Tvardi Therapeutics is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Tvardi Therapeutics has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.43% of the float of Tvardi Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Tvardi Therapeutics has a short interest ratio ("days to cover") of 2.45, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Tvardi Therapeutics has recently decreased by 20.29%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Tvardi Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Tvardi Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Tvardi Therapeutics has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Tvardi Therapeutics this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Tvardi Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    7.40% of the stock of Tvardi Therapeutics is held by insiders.

  • Percentage Held by Institutions

    44.66% of the stock of Tvardi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Tvardi Therapeutics' insider trading history.
Receive TVRD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tvardi Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TVRD Stock News Headlines

The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
See More Headlines

TVRD Stock Analysis - Frequently Asked Questions

Tvardi Therapeutics' stock was trading at $4.30 at the beginning of the year. Since then, TVRD shares have decreased by 76.5% and is now trading at $1.01.

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) posted its earnings results on Friday, November, 13th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.03.

Tvardi Therapeutics (TVRD) raised $60 million in an initial public offering on Friday, January 31st 2014. The company issued 5,000,000 shares at $11.00-$13.00 per share.

Top institutional shareholders of Tvardi Therapeutics include State Street Corp (0.25%).

Shares of TVRD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/13/2026
Today
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:TVRD
Previous Symbol
NASDAQ:TVRD
CIK
1346830
Employees
12
Year Founded
2004

Price Target and Rating

High Price Target
$13.00
Low Price Target
$5.00
Potential Upside/Downside
+830.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.68)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$18.21 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-145.40%
Return on Assets
-91.11%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.87
Quick Ratio
1.87

Sales & Book Value

Annual Sales
$7.14 million
Price / Sales
1.89
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.23 per share
Price / Book
0.45

Miscellaneous

Outstanding Shares
13,340,000
Free Float
12,352,000
Market Cap
$13.47 million
Optionable
Optionable
Beta
0.37

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:TVRD) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners